Drug
Isis 416858
Isis 416858: highest development phase Phase 2, developed by Ionis Pharmaceuticals. 1 trial record tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- Ionis Pharmaceuticals
Trials
| Drug | Phase | Indication |
|---|---|---|
| ISIS 416858 NCT02553889 | Phase 2 | End-stage Renal Disease (ESRD) |
Latest
No recent events.
Follow Isis 416858 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.